New hope for tough leukemias? trial of vodobatinib begins, then stops

NCT ID NCT02629692

Terminated Disease control Sponsor: Sun Pharma Advanced Research Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called Vodobatinib (K0706) in people with chronic myeloid leukemia or a related leukemia who had not responded to at least three other treatments. The trial was split into parts: first in healthy volunteers to check safety, then in patients to find the right dose and see if it could shrink cancer cells. Unfortunately, the trial was terminated early, so we have less information than hoped.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vodobatinib (K0706) capsules
What this could lead to: If it works, this could offer a new treatment option for people with CML or Ph+ ALL who have not responded to other therapies.
What could go wrong: The trial was terminated early, so results are limited. It is an early-phase study, so safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (FOR PART B AND C) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive leukemia, acute lymphocytic, susceptibility to, 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA (FOR PART B AND C) HEALTHY (FOR PART A)

Contacts and locations

Locations

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza

Roma, 00161, Italy
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)

Monza, Milano, 20900, Italy
Baylor University Medical Center

Dallas, Texas, 75226, United States
Board of Regents of the University System of Georgia

Augusta, Georgia, 30912, United States
Centre Hospitalier Lyon Sud

Pierre-Bénite, Rhone, 69495, France
Centre Léon Bérard

Lyon, Rhone, 69373, France
Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium
Debreceni Egyetem

Debrecen, 4032, Hungary
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy
Hammersmith Hospital

London, Greater London, W120HS, United Kingdom
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Huntsman Cancer Institute University of Utah

Salt Lake City, Utah, 84112, United States
ICO Badalona - Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, 08916, Spain
Institut Paoli Calmettes

Marseille, Bouches-du-Rhône, 13273, France
Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca

Cluj-Napoca, 400124, Romania
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori

Meldola, Forli - Cesena, 47014, Italy
King's College Hospital

London, Greater London, SE5 9NU, United Kingdom
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Meenakshi Mission Hospital & Research Centre

Madurai, Tamil Nadu, 625107, India
Memorial Sloan Kettering Cancer Center - MAIN

New York, New York, 10065, United States
Ospedale Sant'Eugenio

Roma, 00144, Italy
Prince Aly Khan Hospital

Mumbai, Maharashtra, 400010, India
Sahyadri Specialty Hospital

Pune, Maharashtra, 411004, India
Spitalul Clinic Colentina

Bucharest, 020125, Romania
Spitalul Clinic Municipal Filantropia Craiova

Craiova, 200143, Romania
Tata Medical Centre

Kolkata, West Bengal, 700156, India
Tata Memorial Hospital

Mumbai, Maharashtra, 400012, India
The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, Gyeonggi-do, 6591, South Korea
The Oncology Institute of Hope and Innovation, Innovative Clinical Research Institute

Downey, California, 90241, United States
UCLA Hematologic Malignancy Program

Los Angeles, California, 90024, United States
Uijeongbu Eulji Medical Center, Eulji University

Gyeonggi-do, 11759, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.